2023-507521-41-01Not yet recruitingPhase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pimozide after Multiple Dose Administration in Subjects with Rheumatoid Arthritis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 29 Aug 2023
- Start date
- 23 Oct 2023
- Lead sponsor
- Generos Biopharma Ltd.
- Diseases
- Rheumatoid arthritis
- EU CT number
- 2023-507521-41-01
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mbal Lyulin EAD | Sofiya | Bulgaria | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.